All In Biotech

Drug Trial Radar · NCT07391878

Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.

Open-Label Study to Evaluate the Safety and Efficacy of Two Doses of TRG-200 KIT in Patients With Refractory Overactive Bladder (OAB) : A Pilot Study

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 15, 2026

Primary completion

Dec 15, 2027

Study completion Dec 15, 2027

Sponsor

Lead sponsor
Trigone Pharma Ltd.Industry
Sponsor type
Industry
First posted
Feb 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, single-center pilot study designed to evaluate the safety, tolerability, and preliminary efficacy of TRG-200 KIT, an intravesical sustained-release oxybutynin formulation, in adult patients with refractory overactive bladder (OAB). The study includes an adaptive two-stage design with initial dose evaluation of two dose levels (150 mg and 300 mg oxybutynin) followed by expansion using the selected dose. TRG-200 KIT is administered via monthly intravesical instillation and aims to provide prolonged local bladder exposure while minimizing systemic absorption and anticholinergic adverse effects.

Conditions

  • Overactive Bladder (OAB)

Interventions

  • TRG-200 KITDrug

    TRG-200 KIT is administered intravesically as a sustained-release formulation. The investigational product consists of a Carbopol gel matrix followed by intravesical instillation of oxybutynin via a urethral catheter, forming a prolonged-release delivery system within the bladder. The intervention is designed to provide sustained local bladder exposure while minimizing systemic absorption and anticholinergic adverse effects.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Average Number of Micturitions per 24 HoursTime frame: Baseline to Week 12
  2. Change From Baseline in Average Number of Urgency Episodes per 24 HoursTime frame: Baseline to Week 12
  3. Change From Baseline in Average Number of Urgency Urinary Incontinence (UUI) Episodes per 24 HoursTime frame: Baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shaare Zedek Medical Center

    Jerusalem, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.